Latest Market Research Updates

Antibody Drug Conjugate Market Is Projected To Reach USD 9.93 Billion By 2025

The global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.

Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.

Seattle Genetics and Roche are leading the antibody drug conjugate market in terms of market share. Until 2017 only two ADCs were commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer’s products were approved to be marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been estimated that over the forecast period, Pfizer is anticipated to gain a significant market share.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: sales@grandviewresearch.comFor More Information: www.grandviewresearch.com

Injection Pen Market Is Estimated To Generate $67.9 Billion By 2025

The global injection pens/injectable pens/pen injectors market is expected to reach USD 67.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 9.4% CAGR during the forecast period. High demand for these devices for management of various chronic as well as acute diseases and increasing awareness in developing regions are key factors expected to drive the market.

Injectable pens have witnessed significant success in improving patient convenience during management of chronic disease, a process that might include administering intermittent injections. These devices are more convenient and affordable than other delivery systems. Ongoing studies on the same to assess their applications in management of other diseases, including but not limited to Hepatitis C and cancer, is expected to ensure swift market growth through 2025.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/injection-pens-market

Further key findings from the study suggest:

Rising incidence of diseases such as diabetes and arthritis is primarily boosting market growth
Increase in government healthcare expenditure and availability of favorable healthcare insurance policies in developed as well as developing countries is driving the market
By product, reusable injectable pens are the largest and fastest growing segment owing to the advantages associated with them such as cost effectiveness and patient convenience. Commercially available reusable injectable pens mainly include Novopen, Luxura, Berlipen, AllStar, NovoRapid, basalgar, Bydureon, Epipen and Genotropin
By dosage, variable dosage is the fastest growing segment. Some of the customizable variable pens are UnoPen, ServoPen and Ypsopen by Ypsomed, Madie by SHL Group, and Evo pen by Copernicus
North America dominates the market, followed by Europe. Technological advancements and increase in incidence of osteoporosis, arthritis, and anaphylaxis are factors that can be attributable to its largest market share
Asia Pacific is expected to be the fastest growing region over the forecast period. Better accessibility to healthcare, coupled with constantly increasing healthcare expenditure in the region, is fueling market growth
China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players. This is owing to favorable factors such as availability of labor and raw materials at significantly lower prices as compared to other regions
Key players in the market include Owen Mumford Ltd.; GlaxoSmithKline plc; Eli Lilly and Company; Mylan N.V.; AstraZeneca; Novo Nordisk; Sanofi; and Sandoz Inc.

About Grand View Research

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Protein Engineering Market Is Projected To Reach $3.09 Billion By 2025

The global protein engineering market is expected to reach USD 3.09 billion by 2025, according to a new report by Grand View Research, Inc. The market is driven by presence of regulatory authorities consistently striving to reduce time and cost involved in the drug discovery process. One such example is the launch of critical path initiative by U.S. FDA, for incorporation of advanced technologies, such as protein engineering, in drug discovery processes. Moreover, this facilitates prediction of probable adverse reactions & toxicity and improves efficacy of target molecules early on, resulting in lowered drug attrition rates in the later stages. This is anticipated to help control overall expenditure. Rise in R&D expenditure by countries indicates the urgent need for adoption of these tools in all drug discovery and development processes.

The rising number of government initiatives aimed at enhancing protein engineering capabilities is anticipated to present the market with high growth potential. This has resulted in a significant rise in number of research activities & programs and fund allotment for R&D. For instance, Protein Engineering Network of Centres of Excellence (PENCE) contributed approximately USD 1.0 million for proteomics projects and hosted conferences on proteomics in Canada as an effort to broaden research associated with this technology.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/protein-engineering-market

Further Key Findings From the Report Suggest:

Hybrid approach is predicted to observe exponential growth as a consequence of technological superiority and ability to overcome the shortcomings associated with the aforementioned technologies
Software & services is expected to emerge as the fastest growing segment owing to high inclination of companies to outsourcing of services to achieve overall cost-efficiency
Monoclonal antibodies held the largest share in protein-type segment due to development of these antibodies on a large scale through extensive adoption of these engineering tools
North America held a substantial share, which can be attributed to extensive research activities that are likely to provide high potential growth platform through consistent usage in this region
The market in Asia Pacific is projected to exhibit exponential growth over the coming years owing to rising awareness pertaining to benefits of protein engineering and increasing disposable income
The competition is marked by players employing strategies such as mergers & acquisitions and distribution agreements resulting in significant growth in their market share

About Grand View Research

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Mouth Ulcers Treatment Market is Projected To Reach $1.32 Billion By 2026

The global mouth ulcers treatment market size is projected to reach USD 1.32 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 3.8% during the forecast period. Increasing geriatric population and rising awareness towards oral hygiene are among the key trends stimulating market growth.

Growing global geriatric population is poised to trigger the number of cases of mouth ulcers. As per the findings of the United Nations Organization (UNO), population base of age 60 years or older across the globe was 962.0 million in 2017, which was more than twice as large as in 1980, when the population was 382.0 million. With upswing in the demand for denture fittings in this population, rise in the incidences of improper fittings and deficiency of vitamin B & folic acid is anticipated. Such incidents can lead to mouth ulcers.

Newly fitted dentures takes some time to adjust. During the procedure, inner area of the mouth remains moist for a certain period. Such conditions favor fungal infection leading to ulcer. Older population often suffer from such conditions, due to which they are prone to oral problems. In addition, deficiency of vitamins is a common phenomenon observed among geriatric population, which also increases the probability of suffering from mouth ulcer.

Rising awareness regarding oral hygiene in developing countries is also estimated to drive the market over the forecast period. Campaigns on oral hygiene in rural areas of developing countries are working in favor of the market. For instance, every year, Colgate-Palmolive Company conducts an oral health month in rural areas of India in order to impart awareness regarding oral hygiene. Such initiatives are expected to encourage people to take up necessary treatments. Furthermore, rise in tobacco usage in countries such as U.K. and Mexico is projected to boost the rate of mouth ulcers, thereby benefitting the growth of the market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/mouth-ulcers-treatment-market

Further key findings from the report suggest:

Analgesics and Corticosteroids are poised to exhibit the highest CAGR during the forecast period. These are the most prescribed drugs by doctors and are easily available
By 2026, Asia Pacific is likely to dominate the mouth ulcer treatment market with a share of around 63.0%. Increasing awareness pertaining to oral hygiene and treatment and rising prevalence of aphthous ulcers are likely to supplement the growth of the market
Some of the key companies present in the market are Blistix Inc., Church & Dwight Co., Inc., 3M, Colgate-Palmolive Company, Pfizer, Bristol-Myers Squibb (BMS), and others are expected to dominate the market over the forecast period.

About Grand View Research

Acne Drugs Market Is Projected To Reach $5.9 Billion By 2025

The global acne drugs market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR during the forecast period. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.

Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/acne-drugs-market

Further key findings from the report suggest:

By type, inflammatory acne captured more than 50.0% of the market in 2017. Comedonal acne were ranked second-largest, among other types
On the basis of therapeutic class, retinoids led the market in 2017, followed by antibiotics. This trend is likely to continue through 2025
The treatment paradigm is shifting toward combination therapies and biologics. Combination products are gaining traction due to higher efficacy, convenient dosing, and fewer adverse effects
Topical products dominated the treatment landscape, based on mode of administration. However, introduction of biologics is likely to result in the growth of the injectables segment
S. dominated the major markets and is projected to maintain its lead through 2025, owing to rising disease incidence and ease of access to anti-acne products
Allergan, Bayer, Galderma, Stiefel, and Valeant are some key players operating in this market. Valeant is projected to lead the market in 2025 due to higher adoption of Retin-A micro as well as anticipated launch of pipeline candidates.

About Grand View Research

Antibody Drug Conjugate Market Is Poised To Reach USD 9.93 Billion By 2025

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

About Grand View Research

Endoscopes Market Is Expected To Boost $17.19 Billion By 2025

The global endoscopes market size is expected to reach USD 17.19 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.8% during the forecast period. Growing global geriatric population, high prevalence of gastrointestinal diseases, and rising technological advancements are the key factors contributing to market growth. Rising preference for minimally invasive surgeries (MIS) is also positively influencing the growth of the market.

Endoscopy surgeries are performed for diagnosis as well as treatment of gastrointestinal, gynecological, neurological, and cardiovascular diseases. Emergence of minimally invasive alternatives to open surgeries such as laparoscopy, hysteroscopy, and colonoscopy is boosting the demand for endoscopes. Preference of MIS is increasing owing to smaller incision, reduction in postoperative complications & mortality, and lesser trauma. Furthermore, they are economically viable alternatives to open surgeries.

Availability of technologically advanced endoscopes is also providing a significant push to the market. Market players are undertaking R&D initiatives to improve existing products as well as launch new products, which is expected to bolster the growth of the market. For example, VISERA 4K UHD System is a surgical system lunched by Olympus in 2016 with 55-inch primary operative display for enhancing MIS.

In March 2018, Auris Health, Inc. announced FDA approval of its new robotic endoscopy system, Monarch Platform. In June 2017, Olympus launched 3D surgical endoscope designed to be compatible with VISERA ELITE II system. It uses 3D imaging facilitating depth perception that enables precise surgery. Pentax Medical launched Slim Linear Ultrasound Endoscope (EG-3270UK) in the U.S. in August 2017.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/endoscopes-market

Further key findings from the report suggest:

Flexible endoscopes emerged as the largest product segment in 2017, accounting for more than half of the market revenue
Gastrointestinal endoscopy was the leading revenue contributor in the market, on the basis of applications, in 2017. On the other hand, urology endoscopy is expected to emerge as the fastest growing segment over the forecast period
Hospitals was the largest end-use segment in 2018 in terms of revenue. Ambulatory surgery centers are rapidly gaining popularity and the segment is anticipated to register the highest CAGR during the same period
North America was the dominant regional market in 2017 due to high healthcare expenditure, favorable reimbursement framework, growing elderly population and disease burden, and heightened adoption of technologically advanced products
Asia Pacific is likely to exhibit a lucrative CAGR of 10.6% during the forecast period owing to economic development in emerging countries, improvement in healthcare infrastructure, and increase in awareness about MIS
Olympus Corporation; Ethicon US, LLC; Fujifilm Holdings Corporation; Boston Scientific Corporation; Karl Storz GmbH & Co. KG; Stryker; Medtronic; and CONMED Corporation are the leading players in the endoscopes market.

About Grand View Research

Latest Market Research Updates

Antibody Drug Conjugate Market Is Projected To Reach USD 9.93 Billion By 2025

Injection Pen Market Is Estimated To Generate $67.9 Billion By 2025

Protein Engineering Market Is Projected To Reach $3.09 Billion By 2025

Mouth Ulcers Treatment Market is Projected To Reach $1.32 Billion By 2026

Acne Drugs Market Is Projected To Reach $5.9 Billion By 2025

Antibody Drug Conjugate Market Is Poised To Reach USD 9.93 Billion By 2025

Endoscopes Market Is Expected To Boost $17.19 Billion By 2025

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

Report Abuse

Labels